论文信息 - Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

The radiosensitivity of lymphomas as well as the local targeted delivery of high doses of radiation make radioimmunotherapy (RIT) an attractive therapeutic option. RIT is indeed an underestimated tool. In follicular lymphoma (FL), RIT represents one of the most effective single agents. The two most commonly used radioimmunoconjugates are Y-ibritumomab tiuxetan (Zevalin ) and I-tositumomab, both based on murine anti-Cd20 antibodies. Annals of Oncology letters to the editor

[1] S. Pileri,et al. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. , 2012, Annals of Oncology.

[2] M. Baccarani,et al. A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients. , 2009 .

[3] S. Swerdlow,et al. Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma , 2008, Clinical Cancer Research.

[4] S. Pileri,et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). , 2008, The Lancet. Oncology.

[5] L. Gordon,et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6] M. Gordon. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma , 2009 .